Developers must make important decisions about product formulation and process design to move a drug from preclinical through Phase II trials as quickly as possible. Over-engineering a Phase I or Phase II drug that ultimately fails in the clinic wastes resources. But neglecting sound science during early stages can result in a promising product that may not have a scalable or commercially manufacturing process. That’s can be an even a bigger waste. Anil Kane, Global Head of Formulation Sciences at Patheon, a leader in contract drug manufacturing, explains how to strike the right balance in an article we helped him publish on PharmTech.com, here.